Abstract
Endometrial cancer (EC) is one of the most common gynecological malignancies in women, accompanied by the increasing incidence and decreasing age of onset. Pyroptosis plays an important role in the occurrence and development of malignant tumors. However, the relationship between pyroptosis-related genes and tumor prognosis remains unclear. In this study, analyzing the expression levels and survival data of 33 pyroptosis-related genes in the Cancer Genome Atlas (TCGA) between normal samples and tumor samples, we obtained six pyroptosis-related prognostic differentially expressed genes (DEGs). Then, through the least absolute shrinkage and selection operator (LASSO) regression analysis, a gene signature composed of six genes (GPX4, GSDMD, GSDME, IL6, NOD2 and PYCARD) was constructed and divided patients into high- and low-risk groups. Subsequently, Kaplan-Meier (KM) plot, receiver operating characteristic (ROC) curve and principal component analysis (PCA) in two cohorts demonstrated that the gene signature was an efficient independent prognostic indicator. The enrichment analysis and immune infiltration analysis indicated that the high-risk group generally has lower immune infiltrating cells and less active immune function. In short, we constructed and validated a pyroptosis-related gene signature to predict the prognosis of EC, which is correlated to immune infiltration and proposed to help the precise diagnosis and therapy of EC.
Highlights
Endometrial cancer (EC) is one of the most common gynecological malignancies in women
By taking the intersection of differentially expressed genes (DEGs) and prognostic genes, we identified six pyroptosis-related prognostic DEGs, namely Glutathione Peroxidase 4 (GPX4), GSDMD, GSDME, IL6, NOD2 and PYCARD (Figure 2B)
We clearly found that GSDME and IL6 were downregulated in tumors while other four genes were upregulated (Figure 2C)
Summary
Endometrial cancer (EC) is one of the most common gynecological malignancies in women. In 2020, there were 417,367 new cases and 97,370 new deaths worldwide [1]. The number of new cases is increasing while its onset age is gradually decreasing [2]. The prognostic outcomes of EC patients in different stages are obviously different. EC patients should be detected as soon as possible to improve their prognosis. The most common clinical symptom of EC is postmenopausal vaginal bleeding (PMB). This symptom is not specific because only 9% of women with PMB are diagnosed as EC [6]. It is important to screen high-efficiency biomarkers or risk model to improve the prognosis of EC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
